ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 128 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 4.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $2,524,000 | +25.9% | 75,357 | 0.0% | 0.02% | +38.9% |
Q3 2016 | $2,005,000 | +20.6% | 75,357 | 0.0% | 0.02% | +5.9% |
Q2 2016 | $1,662,000 | -24.9% | 75,357 | 0.0% | 0.02% | -26.1% |
Q1 2016 | $2,213,000 | -11.1% | 75,357 | 0.0% | 0.02% | +9.5% |
Q4 2015 | $2,488,000 | -8.6% | 75,357 | 0.0% | 0.02% | -16.0% |
Q3 2015 | $2,723,000 | -19.7% | 75,357 | 0.0% | 0.02% | -16.7% |
Q2 2015 | $3,390,000 | +46.9% | 75,357 | 0.0% | 0.03% | +57.9% |
Q1 2015 | $2,307,000 | -39.8% | 75,357 | 0.0% | 0.02% | -51.3% |
Q4 2014 | $3,832,000 | +28.5% | 75,357 | 0.0% | 0.04% | +2.6% |
Q3 2014 | $2,982,000 | -8.1% | 75,357 | 0.0% | 0.04% | -5.0% |
Q2 2014 | $3,246,000 | +0.3% | 75,357 | -6.9% | 0.04% | -2.4% |
Q1 2014 | $3,237,000 | +8.8% | 80,957 | -25.8% | 0.04% | -2.4% |
Q4 2013 | $2,976,000 | +3.9% | 109,097 | -12.7% | 0.04% | +2.4% |
Q3 2013 | $2,865,000 | +29.4% | 125,000 | 0.0% | 0.04% | -6.8% |
Q2 2013 | $2,214,000 | – | 125,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |